PHVS Pharvaris N.V. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1830487 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | FY2025*2025-12-31 | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | 124.48M | 98.56M | 65.58M | 57.38M | 35.79M |
| SG&A expense | 45.34M | 47.12M | 31.34M | 29.34M | 18.35M |
| Operating income | -173.71M | -132.40M | -99.83M | -75.65M | -42.66M |
| Interest expense | — | — | — | 16,105 | 267,510 |
| Pretax income | -173.71M | -132.40M | -99.83M | -75.65M | -42.66M |
| Income tax | 1.99M | 1.83M | 1.05M | 679,087 | 70,117 |
| Net income | -175.70M | -134.22M | -100.88M | -76.33M | -42.70M |
| EPS (basic) | -2.97 | -2.48 | -2.63 | -2.27 | -1.40 |
| EPS (diluted) | -2.97 | -2.48 | -2.63 | -2.27 | -1.40 |
| Weighted avg. shares (diluted) | 59.16M | 54.02M | 38.39M | 33.59M | 30.41M |
| Banking | |||||
| Net interest income | 6.54M | 5.47M | 224,494 | -16,105 | -267,510 |
| Balance sheet | |||||
| Cash & equivalents | 291.68M | 280.73M | 391.23M | 161.84M | 209.35M |
| Receivables | 4.55M | 2.94M | 1.04M | 382,468 | 700,079 |
| PP&E, netmay include right-of-use assets (IFRS) | 642,470 | 667,000 | 223,678 | 193,474 | 108,098 |
| Total assets | 301.45M | 291.37M | 398.69M | 167.73M | 212.09M |
| Total liabilities | 30.18M | 23.61M | 14.65M | 18.47M | 7.14M |
| Shareholders' equity | 271.27M | 267.76M | 384.05M | 149.26M | 204.95M |
| Cash flow statement | |||||
| Operating cash flow | -137.07M | -120.13M | -93.05M | -67.16M | -44.60M |
| Capital expenditure | 164,619 | 538,086 | 89,984 | 124,296 | 130,032 |
| Free cash flow | -137.24M | -120.67M | -93.14M | -67.29M | -44.73M |
| Investing cash flow | -164,619 | -538,086 | -89,984 | -124,296 | -130,032 |
| Financing cash flow | 160.61M | 2.68M | 325.39M | 8.65M | 143.67M |
| Stock-based compensation | 19.05M | 16.21M | 10.66M | 11.35M | 8.20M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.